HAPPENING NOW
Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission f…
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international Phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Cli…
Read full article on MedicalxpressAI summaries can be wrong sometimes—always verify important details using the source article.
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNow